Security Reports > Caladrius Biosciences

Caladrius Biosciences
Data Breaches, Cyber Attacks and Security Report

https://caladrius.com  ᛫  Biotech & Pharmaceuticals
Last updated July 2, 2020

Caladrius Biosciences Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Caladrius Biosciences is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Caladrius Biosciences

Caladrius Biosciences (NASDAQ: CLBS) is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease. The company was founded in 1980 and was formerly known as Corniche Group Inc, Phase III Medical Inc and NeoStem, Inc.


Data Breaches and Security News


Security Report for Caladrius Biosciences

Want a security rating for your organization?

This report shows a preliminary security rating for Caladrius Biosciences. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Caladrius Biosciences's security performance with other companies